<div id="readability-page-1">Boston Scientific (NYSE:BSX - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report issued on Saturday.<div>Get Boston Scientific alerts:</div><ul><li>Beware the Death Cross: 3 Stocks Triggering This Spooky Signal</li></ul>A number of other equities research analysts also recently weighed in on the stock. Erste Group Bank downgraded shares of Boston Scientific from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, October 3rd. Robert W. Baird lifted their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, October 1st. Canaccord Genuity Group cut their price target on Boston Scientific from $132.00 to $131.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday. Leerink Partners raised their price target on Boston Scientific from $127.00 to $128.00 and gave the stock an &#34;outperform&#34; rating in a research report on Wednesday, October 1st. Finally, Evercore ISI reiterated an &#34;outperform&#34; rating on shares of Boston Scientific in a report on Wednesday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of &#34;Buy&#34; and a consensus target price of $124.85.Read Our Latest Research Report on BSX<h2>Boston Scientific Stock Down 0.5%</h2><ul><li>3 Healthcare Stocks Using AI to Drive Growth</li></ul>NYSE BSX opened at $95.61 on Friday. The stock has a market capitalization of $141.74 billion, a P/E ratio of 51.13, a price-to-earnings-growth ratio of 1.94 and a beta of 0.67. Boston Scientific has a 52 week low of $85.98 and a 52 week high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The stock has a fifty day moving average of $98.64 and a 200-day moving average of $101.28. Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to analysts' expectations of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The firm's quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, equities research analysts forecast that Boston Scientific will post 2.85 EPS for the current year. <h2>Insider Transactions at Boston Scientific</h2><ul><li>3 Biotech Catalysts Present Major Opportunity</li></ul>In other news, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 143,095 shares of company stock valued at $14,228,950 over the last three months. Company insiders own 0.50% of the company's stock. <h2>Institutional Investors Weigh In On Boston Scientific</h2>Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Brighton Jones LLC grew its holdings in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after acquiring an additional 226 shares in the last quarter. Martingale Asset Management L P grew its stake in Boston Scientific by 304.0% in the first quarter. Martingale Asset Management L P now owns 20,247 shares of the medical equipment provider's stock valued at $2,043,000 after purchasing an additional 15,235 shares in the last quarter. Compound Planning Inc. grew its stake in Boston Scientific by 9.0% in the first quarter. Compound Planning Inc. now owns 10,495 shares of the medical equipment provider's stock valued at $1,059,000 after purchasing an additional 864 shares in the last quarter. 1832 Asset Management L.P. increased its position in shares of Boston Scientific by 11.1% during the 1st quarter. 1832 Asset Management L.P. now owns 848,147 shares of the medical equipment provider's stock worth $85,561,000 after purchasing an additional 84,585 shares during the last quarter. Finally, Groupe la Francaise raised its stake in shares of Boston Scientific by 13.1% during the 1st quarter. Groupe la Francaise now owns 335,082 shares of the medical equipment provider's stock worth $33,591,000 after purchasing an additional 38,701 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds. <h2>Boston Scientific News Roundup</h2>Here are the key news stories impacting Boston Scientific this week:<ul> <li>Positive Sentiment: RBC Capital continues to rate BSX as an &#34;outperform,&#34; reinforcing buy-side support from a major bank and likely helping demand for shares. RBC Capital maintains Boston Scientific (BSX) outperform recommendation</li> <li>Positive Sentiment: Royal Bank of Canada analyst commentary suggests upside ahead for BSX, adding another institutional voice expecting price appreciation. This supports the bullish narrative among analysts. Boston Scientific NYSE: BSX Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says</li> <li>Positive Sentiment: Truist reaffirmed a &#34;buy&#34; rating on BSX, signaling continued analyst confidence even as the firm updated its outlook—this helps underwrite medium-term investor sentiment. Truist Securities maintains Boston Scientific (BSX) buy recommendation</li> <li>Positive Sentiment: Zacks highlights BSX's global expansion push — R&amp;D, AI-driven manufacturing and a focused Emerging Markets effort targeting $1B+ revenue in China for 2025 — a strategic growth catalyst that supports longer-term upside. Boston Scientific's Global Expansion: What's Behind the Growth?</li> <li>Neutral Sentiment: Options flow is active around BSX; Benzinga's options-focused piece notes positioning that can amplify intraday moves but doesn't definitively indicate directional conviction from fundamental investors. Watch open interest and strike concentration for short-term signals. Decoding Boston Scientific's Options Activity: What's the Big Picture?</li> <li>Neutral Sentiment: Informational pieces recap BSX’s multi-year performance; useful for context but unlikely to move the stock today. These highlight solid historical returns that underpin investor confidence. Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 5 Years</li> <li>Neutral Sentiment: Short-term market commentary notes BSX outperformed earlier sessions; useful for momentum traders but not a standalone fundamental driver. Boston Scientific (BSX) Advances While Market Declines</li> <li>Negative Sentiment: Truist cut its price target from $130 to $120 — a downward revision that may cap near-term upside and pressures sentiment despite the maintained &#34;buy&#34; rating. That target trim likely explains some of the selling pressure today. BSX price target lowered by Truist</li> </ul><h2>Boston Scientific Company Profile</h2> (Get Free Report)Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery. Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.<h2>Further Reading</h2><ul><li>Five stocks we like better than Boston Scientific</li><li>3 Stocks to Protect Your Portfolio from the Coronavirus Contagion </li><li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li><li>Compound Interest and Why It Matters When Investing</li><li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li><li>What Are the U.K. Market Holidays? How to Invest and Trade</li><li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li></ul><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Boston Scientific Right Now?</h2>Before you consider Boston Scientific, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

Wall Street Zen downgraded Boston Scientific (NYSE:BSX) from a "buy" to "hold" rating. Despite this, the stock has a consensus "buy" rating with a target price of $124.85. Boston Scientific reported strong quarterly earnings, beating estimates with $0.75 EPS and $5.07 billion revenue. Insiders sold shares recently, and institutional investors adjusted their stakes. The stock opened at $95.61, with a market cap of $141.74 billion.

Boston Scientific (NYSE:BSX) Downgraded by Wall Street Zen to "Hold"